{"name":"Ozlem Goker-Alpan","slug":"ozlem-goker-alpan","ticker":"","exchange":"","domain":"","description":"Ozlem Goker-Alpan is a Turkish-American physician-scientist whose work focuses on lysosomal storage disorders and rare genetic diseases. She is the founder and chief medical officer of the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), a nonprofit organization based in Fairfax, Virginia.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQdXZpcmFBS1RZd0N2YjNHd01LV0lhTmpwMF9sbHpDUm5NX21OQjF4Ui1WOUFYTHBoN21ybEhBNHdKd09UeFl0SVA1OEVrMzZpNUdwVUZwM3pmd0tYWWx6TVZxSWJ1aFZhaE5vbl9qRlZDZVFXd05zYXZjSDVGQXF0T1Z3RUpLcXJYWmo5MFZwRFozbnljT3dCTml1azlCUGFPOGU2X3pyM2txWVMtOS0yOHN0RktScmxwQlFraXItRGoyZV9oRklaaFBMZ1FnZXhPQ25BN1cxUWdDUXZpMV9yNlNsZlVQdw?oc=5","date":"2026-01-20","type":"pipeline","source":"BioSpace","summary":"Aro Biotherapeutics to Present Clinical Update from its Pompe Disease Program at the 22nd Annual WORLDSymposium - BioSpace","headline":"Aro Biotherapeutics to Present Clinical Update from its Pompe Disease Program at the 22nd Annual WORLDSymposium","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5mckhXYUNwRk1GcTBCblFpcTc2R000RzZYTThUNy11Tl94TnFPTE0tRFdITUJvTklRS3hvVGZYNmRGUVFZZE44TDhNSUhoZVVPdWdXQ01STnlmQnRXcVJJ?oc=5","date":"2026-01-10","type":"regulatory","source":"Nature","summary":"Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension - Nature","headline":"Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extens","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSnpfN25JM09HY0RQNDd1RTJOd0oxWDV0WDRnc01DWHRBazR3TDJCc3JkSDdOcnd6UmhBNkgtUlhpM0RaLU83VVhseXl2YnlrSjVmZ1oxYVNuSkxpSXBFb293bFlpRFFpTm1UdWw5YnNyNnZ3YTAxbFMzZ2E1c0tSQk5maFg5RnUybU4xZmlKdVQ?oc=5","date":"2025-10-16","type":"pipeline","source":"Frontiers","summary":"Enzyme replacement therapy in infants and very young children with Gaucher disease using velaglucerase alfa: a single-center experience - Frontiers","headline":"Enzyme replacement therapy in infants and very young children with Gaucher disease using velaglucerase alfa: a single-ce","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBqQmRKcEhpNm5abm1vbEN1blRyVG9NMHRraXl2a0g1LVBIZmVHd24zVURrN1dESmpIb0xCVUsxaDBfNWFlLWVPVXpQM0ptWTZUN0R5MUQyQUl0QVV1dkFfU3BQamY2NnJ4RlE?oc=5","date":"2019-06-24","type":"pipeline","source":"Wiley Online Library","summary":"Gaucher Disease in Bone: From Pathophysiology to Practice - Hughes - 2019 - Journal of Bone and Mineral Research - Wiley Online Library","headline":"Gaucher Disease in Bone: From Pathophysiology to Practice - Hughes - 2019 - Journal of Bone and Mineral Research","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}